Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study
Christopher T. Ritchlin, Laura C. Coates, Iain B. McInnes, et al.
Annals of the Rheumatic Diseases (2023) Vol. 82, Iss. 11, pp. 1404-1414
Open Access | Times Cited: 28

Showing 1-25 of 28 citing articles:

Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL
Laura C. Coates, Robert Landewé, Iain B. McInnes, et al.
RMD Open (2024) Vol. 10, Iss. 1, pp. e003855-e003855
Open Access | Times Cited: 18
A unified metric of human immune health
Rachel Sparks, Nicholas Rachmaninoff, William Lau, et al.
Nature Medicine (2024) Vol. 30, Iss. 9, pp. 2461-2472
Open Access | Times Cited: 14
Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: A year in review
Andreas Papapetropoulos, Stavros Topouzis, S P H Alexander, et al.
British Journal of Pharmacology (2024) Vol. 181, Iss. 11, pp. 1553-1575
Open Access | Times Cited: 12
Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies
Philip J. Mease, Joseph F. Merola, Yoshiya Tanaka, et al.
Rheumatology and Therapy (2024)
Open Access | Times Cited: 5
A year in review: new treatments and expanded indications in dermatology in 2024
Lauren M. McGrath, Lila G. McGrath, John R. Edminister
Journal of Dermatological Treatment (2025) Vol. 36, Iss. 1
Open Access
Tumor necrosis factor (TNF) inhibitors for psoriatic arthritis
Giovanni Cagnotto, Matteo Bruschettini, Agata Stróżyk, et al.
Cochrane library (2025) Vol. 2025, Iss. 2
Closed Access
Single-Injection Options for Administering a 320 mg Dose of Bimekizumab: 2 mL Safety Syringe and Auto-injector
Michael Sebastian, Jerry Bagel, Bengt Hoepken, et al.
Dermatology and Therapy (2025)
Open Access
Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies
Philip J. Mease, Lianne S. Gensler, Ana‐Maria Orbai, et al.
RMD Open (2025) Vol. 11, Iss. 2, pp. e005026-e005026
Open Access
Navigating Psoriatic Arthritis: Treatment Pathways and Patient-Specific Strategies for Improved Outcomes
Rubén Queiró, José Antonio Pinto-Tasende, Carlos Montilla
Drugs (2025)
Open Access
Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison
Philip J. Mease, Richard B. Warren, Peter Nash, et al.
Rheumatology and Therapy (2024) Vol. 11, Iss. 3, pp. 817-828
Open Access | Times Cited: 3
A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2023
Gizem Kaykı-Mutlu, Zinnet Şevval Aksoyalp, Leszek Wojnowski, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2024) Vol. 397, Iss. 5, pp. 2949-2970
Open Access | Times Cited: 3
Sequencing of Targeted Therapy in Psoriasis: Does it Matter?
Nicole Boswell, Shikha Singla, Kenneth B. Gordon
American Journal of Clinical Dermatology (2024) Vol. 25, Iss. 5, pp. 795-810
Closed Access | Times Cited: 3
Recent advances in the management of psoriatic arthritis: practical considerations
Stephanie R Harrison, Ban-He Din, Helena Marzo‐Ortega, et al.
Polskie Archiwum Medycyny Wewnętrznej (2024)
Open Access | Times Cited: 2
Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison
Richard B. Warren, Iain B. McInnes, Peter Nash, et al.
Rheumatology and Therapy (2024) Vol. 11, Iss. 3, pp. 829-839
Open Access | Times Cited: 2
Bimekizumab: A Review in Psoriatic Arthritis
Tina Nie, Matt Shirley
Drugs (2024) Vol. 84, Iss. 5, pp. 587-598
Closed Access | Times Cited: 2
Effect of bimekizumab on patient-reported disease impact in patients with psoriatic arthritis: 1-year results from two phase 3 studies
Laure Gossec, Ana‐Maria Orbai, Maarten de Wit, et al.
Lara D. Veeken (2024) Vol. 63, Iss. 9, pp. 2399-2410
Open Access | Times Cited: 2
No difference in clinical parameters and drug retention in PsA patients receiving b/tsDMARD monotherapy versus combination with methotrexate: data from the RABBIT-SpA registry
Anne C. Regierer, David Kiefer, Georg Schett, et al.
RMD Open (2024) Vol. 10, Iss. 3, pp. e004389-e004389
Open Access | Times Cited: 2
Efficacy and Safety of Bimekizumab in Patients With Psoriatic Arthritis With or Without Methotrexate: 52‐Week Results From Two Phase 3 Studies
Iain B. McInnes, Philip J. Mease, Yoshiya Tanaka, et al.
ACR Open Rheumatology (2024) Vol. 6, Iss. 11, pp. 720-731
Open Access | Times Cited: 2
Bimekizumab for the treatment of psoriatic arthritis
Yoshiya Tanaka, Stevan Shaw
Expert Review of Clinical Immunology (2023) Vol. 20, Iss. 2, pp. 155-168
Open Access | Times Cited: 6
Comparative Effectiveness of Bimekizumab in Psoriatic Arthritis: A Model‐Based Meta‐Analysis of American College of Rheumatology Response Criteria
Alan Maloney, Vivek Dua, Ghada F. Ahmed
Clinical Pharmacology & Therapeutics (2023) Vol. 115, Iss. 5, pp. 1007-1014
Open Access | Times Cited: 5
Comparative Effectiveness of Bimekizumab and Ustekinumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison
Philip J. Mease, Richard B. Warren, Peter Nash, et al.
Rheumatology and Therapy (2024) Vol. 11, Iss. 5, pp. 1413-1423
Open Access | Times Cited: 1
Comparative Effectiveness of Bimekizumab and Risankizumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison
Philip J. Mease, Richard B. Warren, Peter Nash, et al.
Rheumatology and Therapy (2024) Vol. 11, Iss. 5, pp. 1403-1412
Open Access | Times Cited: 1
Treatment with Targeted Therapy in Patients with Psoriatic Arthritis and Inadequate Response to Methotrexate: Proposal for a Rational Strategy
Philippe Goupille, Guillermo Carvajal Alegria, Frank Verhoeven, et al.
Rheumatology and Therapy (2024) Vol. 11, Iss. 5, pp. 1065-1079
Open Access | Times Cited: 1
Bimekizumab Efficacy in High-Impact Areas: Pooled 2-Year Analysis in Scalp, Nail, and Palmoplantar Psoriasis from Phase 3/3b Randomized Controlled Trials
Joseph F. Merola, Alice B. Gottlieb, Andreas Pinter, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 12, pp. 3291-3306
Open Access | Times Cited: 1
Impact of bimekizumab and certolizumab pegol on efficacy, safety and osteoblastic activity in radiographic axial spondyloarthritis: results from a phase IIa, multicentre, randomised, double-blind, exploratory study with PET-CT imaging
Xenofon Baraliakos, J. De Jongh, Denis Poddubnyy, et al.
Therapeutic Advances in Musculoskeletal Disease (2024) Vol. 16
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top